Alan Rong - Concepedia

Author

Alan Rong

Astellas Pharma (United States)

Also Known As

A. Rong, Alan Rong, Diao, Guoqing, Rong A, Rong, Alan

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Astellas Pharma (United States)Amgen (United States)Ghent University Hospital Center for Global Development

About

Alan Rong is an author at Astellas Pharma (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	210
2	Biostatistics	3	3	54
3	Health Sciences	2	2	102
4	Public Health	1	1	16
5	Diagnostic Sciences	1	1	51

Alan Rong

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena, New England Journal of Medicine	2013	2.2K
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer Marc Peeters, Timothy Price, Andrés Cervantes, Journal of Clinical Oncology	2010	992
Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials Roger Sidhu, Alan Rong, Steve Dahlberg Clinical Cancer Research Progression-free SurvivalSurgical OncologyMedicineClinical EndpointClinical Trials	2013	51
Analysis of <i>KRAS/NRAS</i> and <i>BRAF</i> mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). Kelly S. Oliner, Jean‐Yves Douillard, Salvatore Siena, Journal of Clinical Oncology PathologyFirst-line TreatmentTreatment VerificationGastrointestinal OncologyClinical Trials	2013	51
Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy Tu Xu, Yixin Fang, Alan Rong, BMC Medical Research Methodology	2015	47
14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) Marc Peeters, Timothy Price, Yevhen Hotko, European Journal of Cancer Supplements Second-line TreatmentOncologyGastrointestinal OncologyPathologyColorectal Cancer	2009	31
Weighted log‐rank test for time‐to‐event data in immunotherapy trials with random delayed treatment effect and cure rate Shufang Liu, Chenghao Chu, Alan Rong Pharmaceutical Statistics Cancer ManagementClinical EndpointImmunologyTreatment EffectImmunotherapy	2018	27
Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer Michel Ducreux, Timothy Price, Yevhen Hotko, Europe PMC (PubMed Central) Second-line TreatmentGastrointestinal OncologyMedicinePathologyColorectal Cancer	2010	23
Biomarker threshold adaptive designs for survival endpoints Guoqing Diao, Jun Dong, Donglin Zeng, Journal of Biopharmaceutical Statistics Biomarker (Medicine)Second StageRight PatientsHealth PolicyMedicine	2018	16
<scp>TITE‐gBOIN</scp>: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades Kentaro Takeda, Qing Xia, Shufang Liu, Pharmaceutical Statistics	2021	15

Page 1